Literature DB >> 29959561

P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).

Zhongyan Hua1, Yue Zhan1, Simeng Zhang1, Yudi Dong1, Min Jiang1, Fei Tan2, Zhihui Liu3, Carol J Thiele3, Zhijie Li4.   

Abstract

The over-expressions of brain-derived neurotrophic factor (BDNF) and its tyrosine kinase receptor TrkB have been reported to induce chemo-resistance in neuroblastoma (NB) cells. In this study, we investigated the roles of P53 and BCL2 family members in the protection of BDNF/TrkB from etoposide-induced NB cell death. TB3 and TB8, two tetracycline (TET)-regulated TrkB-expressing NB cell lines, were utilized. The expressions of P53 and BCL2 family members were detected by Western blot or RT-PCR. Transfection of siRNAs was used to knockdown P53 or PUMA. Activated lentiviral was used to over-express PUMA. Cell survival was performed by MTS assay, and the percentage of cell confluence was measured by IncuCyte ZOOM. Our results showed that etoposide treatment induced significant and time-dependent increase of P53, which could be blocked by pre-treatment with BDNF, and knockdown P53 by transfecting siRNA attenuated etoposide-induced TrkB-expressing NB cell death. PUMA was the most significantly changed BCL2 family member after treatment with etoposide, and pre-treatment with BDNF blocked the increased expression of PUMA. Transfection with siRNA inhibited etoposide-induced increased expression of PUMA, and attenuated etoposide-induced NB cell death. We also found that over-expression of PUMA by infection of activated lentiviral induced TrkB-expressing NB cell death in the absence of etoposide, and treatment of BDNF protected NB cells from PUMA-induced cell death. Our results suggested that P53 and PUMA may be potential targets that mediated the protection of BDNF/TrkB from etoposide-induced NB cell death.

Entities:  

Keywords:  BDNF; Etoposide; Neuroblastoma; P53; PUMA; TrkB

Mesh:

Substances:

Year:  2018        PMID: 29959561      PMCID: PMC6294298          DOI: 10.1007/s10495-018-1467-6

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  37 in total

Review 1.  Anti-apoptosis and cell survival: a review.

Authors:  Liam Portt; Grant Norman; Caitlin Clapp; Matthew Greenwood; Michael T Greenwood
Journal:  Biochim Biophys Acta       Date:  2010-10-20

2.  Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.

Authors:  Kieuhoa T Vo; Katherine K Matthay; John Neuhaus; Wendy B London; Barbara Hero; Peter F Ambros; Akira Nakagawara; Doug Miniati; Kate Wheeler; Andrew D J Pearson; Susan L Cohn; Steven G DuBois
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

3.  Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines.

Authors:  Ute A Sartorius; Peter H Krammer
Journal:  Int J Cancer       Date:  2002-02-10       Impact factor: 7.396

4.  Contribution of ATM and ATR kinase pathways to p53-mediated response in etoposide and methyl methanesulfonate induced DNA damage.

Authors:  Bin Sun; Susan M Ross; Sean Rowley; Yeyejide Adeleye; Rebecca A Clewell
Journal:  Environ Mol Mutagen       Date:  2017-02-14       Impact factor: 3.216

Review 5.  On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology.

Authors:  Carol J Thiele; Zhijie Li; Amy E McKee
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

Review 6.  Tumour suppression by p53: the importance of apoptosis and cellular senescence.

Authors:  Valentina Zuckerman; Kamil Wolyniec; Ronit V Sionov; Sue Haupt; Ygal Haupt
Journal:  J Pathol       Date:  2009-09       Impact factor: 7.996

7.  FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction.

Authors:  D-W Wu; M-C Lee; N-Y Hsu; T-C Wu; J-Y Wu; Y-C Wang; Y-W Cheng; C-Y Chen; H Lee
Journal:  Oncogene       Date:  2014-07-07       Impact factor: 9.867

Review 8.  DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide.

Authors:  P B Jensen; M Sehested
Journal:  Biochem Pharmacol       Date:  1997-10-01       Impact factor: 5.858

9.  Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing.

Authors:  Andrew L Paek; Julia C Liu; Alexander Loewer; William C Forrester; Galit Lahav
Journal:  Cell       Date:  2016-04-07       Impact factor: 41.582

Review 10.  Putting p53 in Context.

Authors:  Edward R Kastenhuber; Scott W Lowe
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

View more
  4 in total

1.  Novel agent DMAMCL suppresses osteosarcoma growth and decreases the stemness of osteosarcoma stem cell.

Authors:  Gen Ba; Zhongyan Hua; Ning Xu; Simeng Zhang; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  Cell Cycle       Date:  2020-05-13       Impact factor: 4.534

2.  Encorafenib enhances TRAIL-induced apoptosis of colorectal cancer cells dependent on p53/PUMA signaling.

Authors:  Zhenqing Sun; Zhigang Qiu; Bin Ma; Zhengkun Wang
Journal:  Cytotechnology       Date:  2020-11-13       Impact factor: 2.058

3.  A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy.

Authors:  Liyu Zhang; Meng Wang; Zeen Zhu; Chenxi Ding; Shengquan Chen; Haibin Wu; Ying Yang; Fengyu Che; Qiao Li; Hui Li
Journal:  Int J Nanomedicine       Date:  2021-05-10

Review 4.  BDNF Therapeutic Mechanisms in Neuropsychiatric Disorders.

Authors:  Amjad H Bazzari; Firas H Bazzari
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.